Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial - Piemonti, Lorenzo; Keymeulen, Bart; Gillard, Pieter; Linn, Thomas; Bosi, Emanuele; Rose, Ludger; Pozzilli, Paolo; Giorgino, Francesco; Cossu, Efisio; Daffonchio, Luisa; Goisis, Giovanni; Ruffini, Pier Adelchi; et al. (Diabetes, obesity & metabolism, 2022)
Keywords: beta cell function; Beta cells; Chemokine receptors; Clinical trials; CXCR2 protein; Diabetes; Diabetes mellitus (insulin dependent); Double-blind studies; Inhibitor drugs; Insulin; Patients; Peptides; phase I‐II study; Placebos; randomized trial; type 1 diabetes